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Cerebro-oculo-facio-skeletal (COFS) syndrome is a recessively inherited rapidly progressive neurologic disorder
leading to brain atrophy, with calcifications, cataracts, microcornea, optic atrophy, progressive joint contractures,
and growth failure. Cockayne syndrome (CS) is a recessively inherited neurodegenerative disorder characterized by
low to normal birth weight, growth failure, brain dysmyelination with calcium deposits, cutaneous photosensitivity,
pigmentary retinopathy and/or cataracts, and sensorineural hearing loss. Cultured CS cells are hypersensitive to
UV radiation, because of impaired nucleotide-excision repair (NER) of UV-induced damage in actively transcribed
DNA, whereas global genome NER is unaffected. The abnormalities in CS are caused by mutated CSA or CSB
genes. Another class of patients with CS symptoms have mutations in the XPB, XPD, or XPG genes, which result
in UV hypersensitivity as well as defective global NER; such patients may concurrently have clinical features of
another NER syndrome, xeroderma pigmentosum (XP). Clinically observed similarities between COFS syndrome
and CS have been followed by discoveries of cases of COFS syndrome that are associated with mutations in the
XPG and CSB genes. Here we report the first involvement of the XPD gene in a new case of UV-sensitive COFS
syndrome, with heterozygous substitutions—a R616W null mutation (previously seen in patients in XP comple-
mentation group D) and a unique D681N mutation—demonstrating that a third gene can be involved in COFS
syndrome. We propose that COFS syndrome be included within the already known spectrum of NER disorders:
XP, CS, and trichothiodystrophy. We predict that future patients with COFS syndrome will be found to have
mutations in the CSA or XPB genes, and we document successful use of DNA repair for prenatal diagnosis in
triplet and singleton pregnancies at risk for COFS syndrome. This result strongly underlines the need for screening
of patients with COFS syndrome, for either UV sensitivity or DNA-repair abnormalities.
Introduction
Although initially reported as early as 1971, by Lowry et
al., the cerebro-oculo-facio-skeletal syndrome (COFS syn-
drome [MIM 214150]) was delineated by Pena and Shok-
eir in 1974, as an autosomal recessive, progressive brain
and eye disorder leading to microcephaly, with cerebral
atrophy, hypoplasia of the corpus callosum, hypotonia,
severe mental retardation, cataracts, microcornea, optic
atrophy, progressive joint contractures, and postnatal
growth deficiency. Even in the earliest reports, there ap-
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peared to be severe perinatal lethal forms,with similarities
to other early-onset disorders, such as Cockayne syn-
drome (CS [MIM 216400–216411]), CAMFAK syn-
drome (CAMFAK [MIM 212540]), and, possibly, Neu-
Laxova syndrome (NLS) (NLS [MIM 256520]). Other
researchers reported entities at the milder end of this phe-
notypic spectrum, such as Martsolf syndrome (Martsolf
[MIM 212720]), CAHMR syndrome (CAHMR [MIM
211770]), and MICRO syndrome (MICRO [MIM
600118]). All these entities appear to be inherited in an
autosomal recessive fashion. COFS syndrome and CS are
both associated with neurodegeneration and cataracts,
and they are usually both considered within the same
differential diagnosis, but COFS-syndrome eye defects
(i.e., microcornea with optic atrophy) appear to be more
severe than those usually associated with CS (i.e., pig-
mentary retinopathy). Also, cutaneous photosensitivity
was not noted in the patients originally diagnosed as hav-
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ing COFS syndrome, so these entities have been consid-
ered to be distinct from each other, until the past few
years.
A biochemical defect and an associated genetic mu-
tationwere first found, in a patient withCOFS syndrome,
by Hamel et al. (1996). This severe case showed prenatal-
onset growth deficiency, severe microcephaly, micro-
phthalmia with no cataracts, cleft palate, cutaneous pho-
tosensitivity, and brain atrophy with no calcifications.
Skin fibroblasts revealed extreme cellular sensitivity to
UV, comparable to that in classic xeroderma pigmento-
sum (XP [MIM 278700–MIM 278810]). Such XP-like
defective nucleotide-excision repair (NER), in combina-
tion with the clinical symptoms, suggested a diagnosis of
the very rare XP-CS complex (Moriwaki et al. 1996).
Complementation analysis indicated that the XPG gene
was affected in this patient, and this was confirmed by
mutation analysis (Nouspikel et al.1997). Sigmundsson
et al. (1998) reported another, similar patient with COFS
syndrome, with both microphthalmia and cataracts and
with an XPG-gene defect.
Families related to the Manitoba Aboriginal popu-
lation within which COFS syndrome originally was re-
ported have also demonstrated cellular UV sensitivity
consistent with CS, with irreversible transcription in-
hibition and normal global genome NER (GG-NER)
after UV exposure. Such patients present with both pre-
natal-onset growth deficiency and microphthalmia with
cataracts but with no obvious cutaneous photosensitiv-
ity. They manifest a homozygous 2-nt deletion in the
CSB gene, resulting in a truncated polypeptide, and
identical mutations have been identified in their parents
and in archival pathology tissue from other patients
with COFS syndrome who are from this region (Meira
et al. 2000). Recently, a second child was reported with
COFS syndrome and a homozygous 177-bp deletion in
the CSB gene (Powell et al. 2000). We now report a
child with COFS syndrome who has a unique mutation
in a third DNA-repair gene, XPD, and we demonstrate,
in a triplet pregnancy and in a subsequent singleton
pregnancy, how the finding of abnormal DNA repair
can be used for prenatal diagnosis.
Subjects, Material, and Methods
Clinical Report
This male infant was the prenatally growth-deficient
1.4-kg product of a 37-wk pregnancy and was born to
nonconsanguineous Ashkenazi Jewish parents who pre-
viously had experienced two spontaneous abortions. The
mother gained only 5 kg during the pregnancy, and am-
niocentesis performed for maternal age of 35 years re-
vealed a normal 46,XY karyotype. Results of prenatal
ultrasonography at 16 and 21 wk gestationwere thought
to be normal. There was spontaneous early labor, with
meconium-stained amniotic fluid after rupture of mem-
branes, and this male infant was delivered vaginally, with
Apgar scores of 9 and 9.
Examination revealed severe intrauterine growth de-
ficiency, microcephaly, deep-set small eyes with bilateral
cataracts, a prominent beaked nose, micrognathia, mi-
cropenis with scrotal hypoplasia, finger contractures
with a simian crease on the right, kyphoscoliosis, and
rocker-bottom feet (fig. 1, left). Results of repeat chro-
mosome analysis and metabolic studies, including anal-
yses of organic acids, were all normal. The diagnosis of
COFS syndrome (versus early-onset CS) was made, and
skin-fibroblast analysis for sensitivity to UV radiation
was initiated. At age 17 d the infant had a weight of
1.5 kg, length 39.5 cm, and occipital-facial circumfer-
ence (OFC) 27.5 (all values are 5–6 SD below the ex-
pected means for a term birth), and brain-stem auditory-
evoked responses suggested profound bilateral hearing
impairment. By age 4 mo the cataracts had been re-
moved, and the infant had a weight of 3 kg, length 46
cm, and OFC 31 cm; at age 9 mo there had been little
improvement in his growth (fig. 1, right). On follow-up
at age 13 mo he was noted to be profoundly growth/
developmentally delayed, with sparse hair and a deeply
sunburned face suggesting cutaneous photosensitivity.
No abnormal skin pigmentation or signs of skin cancer
were evident; his sparse hair was not examined micro-
scopically, nor was the sulfur content determined. He
had severe microcephaly with small, deep-set eyes, mi-
crognathia, and extensive joint contractures. He had re-
peated hospital admissions, for respiratory difficulties
secondary to his neurodegenerative disease, and he died
at age 3 years.12
Cell Cultures and Strains
Response to UV radiation was evaluated in human dip-
loid fibroblast cell cultures derived from skin-biopsy cul-
tures after the parents had signed informed-consent forms
approved by local institutional review boards. Cell strains
used were 96RD362 (proband), C5RO (normal fibro-
blasts), XP25RO (XP complementation group A [XPA]),
XP1BA (complementation group B [XP-B]), XP21RO
(complementation group C [XP-C]), XP6BE (comple-
mentation group D [XP-D]), XP2BI (complementation
group G [XP-G]), and CS1AN (CS-B).
UV-Survival Curves
Survival assays were performed at Rotterdam, as de-
scribed by Hamel et al. (1996). Sparse petri-dish cultures
were exposed to graded UV doses and were further in-
cubated for 4–6 d. Subsequently, proliferative activity
was determined by incorporation of tritiated thymidine
measured by scintillation counting (Rotterdam). Sur-
vival was also studied at the Armed Forces Institute of
Pathology, by means of six-well-cluster dishes inoculated
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Figure 1 Clinical appearance of patient with COFS syndrome. Patient is shown at age 3 wk (left) and at age 9 mo (right).
with 20,000 cells/well, with irradiation after 1 d of cul-
ture, and the cells were counted by a particle counter
after an additional 3–5 d. Results of both methods were
similar and were identical to those of classic cloning
assays.
Unscheduled DNA Synthesis (UDS) and
Complementation Analysis
GG-NER activity was assessed as UV-induced incor-
poration of tritiated thymidine (i.e., UDS), as described
elsewhere (Vermeulen et al. 1993). Fixed cells were proc-
essed for autoradiography, and silver grains were
counted above 25–50 non–S-phase cells. Complemen-
tation analysis was performed as described byVermeulen
et al. (1993) and Hamel et al. (1996), by means of pair-
wise fusion of cell strains preloaded with different types
of polystyrene beads. UDS was determined 2 d after
fusion in heterokaryons, and mononuclear cells were
differentiated on the basis of their bead content.
Inhibition of DNA Synthesis, by UV
Cell cultures were prelabeled overnight with [14C]-thy-
midine and were exposed to various doses of UV. To
assess recovery from inhibition of nucleic-acid synthesis,
cells were cultured for an additional 16 h, and the rates
of S-phase–dependent DNA synthesis were measured by
liquid-scintillation counting of pulse-label–incorporated
[3H]-thymidine. Relative rates of DNA synthesis were
assessed on the basis of [3H]:[14C] ratios and were ex-
pressed as percentages of unirradiated cells, as described
elsewhere (Sijbers et al. 1998).
Mutation Analysis
Initial mutation screening was performed by means of
restriction-enzyme fingerprinting (Liu and Sommer
1995). Four overlapping XPD-gene cDNA fragments
were obtained by reverse transcriptase–PCR and were
digested with various mixtures of restriction enzymes.
The combinations used were as follows: fragment 1 (cov-
ering codons 17 through 188), NcoI-AvaII-SacI and
NcoI-NspI-MboII; fragment 2 (codons 175 through
346), AluI-DdeI and BglI; fragment 3 (codons 335
through 557), NcoI-BglI-BpmI and NcoI-AvaII-PvuII;
and fragment 4 (codons 553 through 7604), BamHI-
AccI and RsaI-HhaI. Digested fragments were end-la-
beled by means of g-[32P]-ATP, were heat-denatured, and
were separated on native polyacrylamide gels. Standard
robotic bidirectional sequencing of cDNA fragments 3
and 4 was performed by BaseClear.
Results
DNA-Repair Studies
UV sensitivity of cells.—An initial study (by the Armed
Forces Institute of Pathology) showed the cells to have
D37 of 0.6 J/m
2 and D10 of 1.4 J/m
2, versus 4–8 and 10–17
J/m2, respectively, for normal controls. This result was
confirmed by a Rotterdam study using a slightly different
method, showing 10-fold–increased sensitivity to UV,
comparable to that in patients with severe XP who were
from complementation group A (see fig. 2A). Since CS
cells with a defect in transcription-coupled NER (TC-
NER) normally show no greater than approximately
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Figure 2 DNA-repair characteristics of patient’s fibroblasts (black symbols) and of normal C5RO cells (white symbols). Standard-error
bars are shown wherever they exceed symbol size. A, UV-survival curves, compared to typical XP-A and XP-C strains measured in a separate
experiment. B, GG-NER activity in mononuclear cells of patient (black bars) mononuclear cells from fusion partner (representative of XP group
B, D, or G) (white bars), and heterokaryons in fusion experiments (gray bars), measured as UDS and represented as a percentage of that in
normal C5RO cells tested in the same experiment. C, Residual rates of overall DNA synthesis 16 h after exposure to various UV doses. Typical
responses of XP-A and CS-B cells are from a separate experiment.
fourfold-increased sensitivity, presence of the XP-CS
complex—in which GG-NER, as well as TC-NER, is
affected—was suspected.
UDS.—The overall rate of NER activity, measured
autoradiographically in single cells (i.e., UDS), was se-
verely impaired and reduced to 1%–2% (see fig. 2B),
which is comparable to that in the most severe cases of
XP, in complementation groups A, B, and G and which
confirms a generalized defect in both the GG-NER and
the TC-NER modes.
Inhibition of DNA synthesis.—UV-induced DNA le-
sions act as a block to RNA polymerase II–dependent
transcription. Recovery from inhibition of RNA synthe-
sis depends on an intact TC-NER process; consequently,
the overall rate of replicative-DNA synthesis is tempo-
rarily depressed as well. Whereas normal cells exposed
to 2–5 J/m2 of UV regain most of their original DNA
replication in !16 h, the patient’s fibroblasts failed to
do so, to an extent similar to that in typical patients
with either CS or severe XP (see fig. 2C). In conclusion,
the patient’s cells suffered from an almost complete im-
pairment of NER, in both GG-NER and TC-NER, a
biochemical defect comparable to that usually found in
patients with classic XP patients who have defective
XPA, XPB, or XPG genes; however, since the clinical
picture was clearly distinct from that of XP, a further
genetic study was indicated.
Gene Assignment and Mutation Analysis
To identify the responsible gene, we performed com-
plementation studies by cell fusion. Restoration of NER
activity occurred after fusion with cells from XP-B and
XP-G but not after fusion with cells from XP-D (see fig.
2B). Involvement of theXPD gene was further evaluated
by restriction-enzyme fingerprinting of four overlapping
fragments of the cDNA. We found no evidence for
changes in fragments 1–3, whereas at least three new
bands appeared in fragment 4, with both enzyme di-
gestions (see the example shown in fig. 3A), presumably
suggesting the presence of two heterozygous mutations
in the 3′ quarter of the XPD-gene cDNA. Subsequent
cDNA sequencing revealed two heterozygous missense
base transitions in fragment 4 (see fig. 3B) and no mu-
tations in fragment 3. On the protein level, one transition
results in a change, R616W, that, in an earlier study
(Lehmann 2001), had been reported to be a null mu-
tation occurring in several patients in XP-D. The second
mutation, presumably in the other allele, appears to be
responsible for the patient’s phenotype, and it causes a
new and unique amino-acid substitution, D681N. This
change is unlikely to represent a polymorphism, since
the normal aspartic acid residue shows complete evo-
lutionary conservation in all known XPD genes (see fig.
3C).
Prenatal Diagnosis
Prenatal diagnosis was requested in a subsequent trip-
let pregnancy, had which had been by in vitro fertili-
zation. The triplets consisted of one singleton (fetus A)
and two MZ twins (fetuses B and C). Cell cultures were
grown from chorionic villus (CV) samples obtained, at
10 and 12 wk of gestation, from the singleton and from
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Table 1
Prenatal Diagnosis of XP-CS Complex in Two Pregnancies in
One Family, after Birth of Proband: UV-induced UDS in CV
Cells, Amniocytes, and Skin Fibroblasts
SOURCE
RESULTS OF UDSa
(average no. of
grains/nucleus)
Fetus(es)
Normal
Control(s)
Pregnancy 1:
Singleton A, CV cells 9.2 50,70
Twin B/C, CV cells (two populations) 3.2, 35 65
Pregnancy 2:
CV cells 54 36
Amniocytes 43 53
Skin fibroblasts:
Index patient (COFS syndrome) 1.3 46
Fetus C (demise)b 32 48
a At UV exposure of 16 J/m2.
b Fetus C suffered intrauterine demise; no cells were available
from either fetus A (which suffered selective reduction) or child B
(who was healthy).
Figure 3 Molecular genetic analysis of XPD gene. A, Restriction-enzyme fingerprinting of 3′ cDNA fragment 4 (shown in panel D),
digested with RsaI-HhaI. Red arrows indicate new bands appearing in patient’s DNA (lane P), compared to normal sequence (lane N). B,
Relevant parts of XPD sequence readout. Both mutations found were heterozygous. C, Conservation of XPD amino acids around mutation
D681N. Rodent p Mus musculus and Cricetulus griseus; fish p Xiphophorous maculatus. D, Bar representation of XPD protein with seven
helicase domains, mutations found in the proband (black) and in two other patients in XP-D who have symptoms of CS (gray) (from Lehmann
2001).
the common placenta of twins B and C, and the cultures
were shipped from New York to Rotterdam, for further
analysis. Table 1 shows results of UDS studies of sin-
gleton A and of twins B and C. CV cells of singleton A
showed a deficiency of DNA-repair synthesis (UDS
13%–18% of that in normal controls), indicating that
the fetus was affected. The UDS results for the CV cells
of twins B and C were complicated by the presence of
two different cell populations in an ∼1:1 ratio. Cells
with very low grain numbers (i.e., 0–10 grains/nucleus)
were mixed with cells with grain numbers in a normal
range (i.e., 22–65 grains/nucleus). Recovery of DNA
synthesis was normal (results not shown). These results
could be interpreted in three ways. (1) twins B and C
are not MZ; one is affected, and the other is unaffected.
However, the presence of a shared placenta indicates that
the twins definitely should be MZ. (2) Twins B and C
are both affected, and the UDS-proficient cells originate
from the mother. However, twins B and C (as well as
singleton A) were male; FISH analysis of the CV culture
used for the DNA-repair study demonstrated exclusively
XY cells, excluding maternal cell admixture. (3) Twins
B and C are both unaffected; the UDS-deficient CV cells
originate from singleton A. Since explanations (1) and
(2) had to be rejected, and since cross-contamination in
CV cultures from multiple gestational products is not an
uncommon event (Van den Berg et al. 1999), the final
diagnosis was that singleton A was affected and that
twins B and C were unaffected.
Selective termination of singleton A was performed at
18 wk gestation, and a macerated male fetus was deliv-
ered at 22 wk gestation; thus, there was no possibility
of cell culture for a confirmatory study. Twins B and C
were delivered by cesarean section at 32 wk gestation,
immediately after the intrauterine demise of one of the
twins (i.e., fetus C). DNA-repair study (i.e., UDS; see
table 1) and recovery of DNA synthesis (not shown) in
cultured fibroblasts from twin C confirmed the presence
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Table 2
COFS Syndrome and Similar Syndromes
PARAMETER
STATUSa
COFS
Syndrome
CAMFAK
Syndrome CS
MICRO
Syndrome
CAHMR
Syndrome
Martsolf
Syndrome
General:
Low birth weight /  /  / /
Failure to thrive      
Feeding problems   /   
Mental retardation      
Early death     / 
Seizures      
Wide-set nipples      
Hypertrichosis      /
Genital hypoplasia      
Skeletal:
Kyphoscoliosis   /   
Camptodactyly   /   
Flexion contractures   /   
Abnormal feet   /   
Craniofacial:
Microcephaly      
Cortical atrophy      
Hypoplastic corpus callosum      
Microphthalmia      
Optic atrophy  ?    
Congenital cataracts      
Deep-set eyes      
Prominent nasal root      
Low nasal bridge      
Prominent upper lip      
Maxillary retrusion      
Micrognathia  / /  / /
Prognathism      
Large ears      
Microdontia      
a A plus sign () denotes presence; a minus sign () denotes absence; a plus/minus sign (/) denotes
that results were variable.
of normal NER in this fetus. Examination of the placenta
of the twins revealed multiple anastamoses, which may
have resulted in abnormal blood flow and, thereby, in
the demise of twin C. When this article was accepted
for publication, twin B was age 3 years and healthy. In
a subsequent singleton pregnancy in the same family,
normal UDS was demonstrated in CV cells, but, since
the fetus was female, and since maternal-cell overgrowth
could not be fully excluded, amniocentesis was also per-
formed. Normal DNA-repair capability was confirmed
in the cultured amniocytes (table 1). At the time of the
present study, this girl was age 32 mo and healthy.
Discussion
COFS syndrome is a rare, well-established birth-defect
syndrome that was defined 120 years ago, as occurring
with autosomal recessive inheritance in isolated Mani-
toba families (Pena and Shokeir 1974) characterized by
frequent consanguineous marriages (Pena et al. 1978).
A number of other patients with similar findings have
been reported, resulting in both a further nosological
delineation of COFS syndrome and differentiation from
other, similar clinical entities (Lowry et al. 1971; Scott-
Emuakpor et al. 1977; Lowry 1982; Patton et al. 1989;
Nance and Berry 1992). On the basis of these reports,
significant clinical overlap with other, similar autosomal
recessive eye/brain syndromes—such as CS, CAMFAK
syndrome, MICRO syndrome, Martsolf syndrome, and
CAHMR syndrome (for overview, see table 2)—has be-
come apparent. Because COFS syndrome and CS are
both associated with neurodegeneration and cataracts,
they are usually considered to belong within the same
differential diagnosis, but COFS-syndrome eye defects
(i.e., microcornea with optic atrophy) are more severe
than those usually associated with CS (i.e., pigmentary
retinopathy), and cutaneous photosensitivity was not
noted in the patients originally reported with COFS syn-
drome. The difficulty in delineating such rare progressive
genetic disorders has been well illustrated and discussed
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by various clinicians (Pena et al. 1978; Winter et al.
1981; Warburg et al. 1993), and it has been clear for
some time that a specific biochemical or genetic marker
would be of great benefit.
Key features of COFS syndrome include congenital
microcephaly, with subsequent brain atrophy, reduced
white matter, patchy gray matter, hypotonia, deep-set
eyes with microphthalmia and cataracts, and campto-
dactyly with rocker-bottom feet. Movement is markedly
decreased, leading to joint contractures, and life span
is usually severely limited (Pena and Shokeir 1974; Preus
and Fraser 1974; Pena et al. 1978). In children with
COFS syndrome, failure to thrive is prevalent, because
of feeding problems, aspiration, and repeated lower-
respiratory-tract infections; and, in 8 of the 10 patients
initially diagnosed with COFS syndrome, recurrent-as-
piration pneumonia has led to death at age !30 mo. In
1978, Pena et al. reported longitudinal follow-up of
some of their earlier-reported cases, the results of which
emphasized the progressive nature of this disease and
suggested that it might represent a primary neurode-
generative disorder associated both with progressive
loss of subcortical white matter and myelin and with
the development of intracranial calcifications. Linna et
al. (1982) emphasized the diagnostic usefulness of find-
ing the foci of intracranial calcifications via cranial com-
puted-tomography scans of the lenticular nuclei and
hemispheric white matter of affected siblings withCOFS
syndrome.
Neuropathology studies reported in the initial
publications discussing COFS syndrome revealed gen-
eralized subcortical gliosis and decreased white matter
with reduced myelin content, and Del Bigio et al. (1997)
reported neuropathology in eight children with COFS
syndrome, seven of whom were from the same Mani-
toba Aboriginal families. They noted progressive cor-
tical neuronal loss with patchy absence of myelin and
gliosis in white matter, as well as pericapillary and pa-
renchymal mineralization in the globus pallidus, puta-
men, and cerebral cortex. In older children, there was
severe cerebellar degeneration involving the internal
granular layer and the Purkinje cell layer, and, in the
younger cases, swollen ubiquinated granular cells were
found in the white matter shortly after birth. Such pro-
gressive demyelination with brain calcification is quite
similar to what is seen in the severe infantile form of
CS. In both conditions, intrauterine growth can be close
to normal, but, after birth, growth deficiency is striking
and unrelenting, and it has become increasingly more
difficult to distinguish between early-onset CS and
COFS syndrome in siblings who have congenital cata-
racts, microphthalmia, intracranial calcifications, and
progressive demyelinating diseases similar to early-onset
CS (Linna et al. 1982; Lowry 1982; Lerman-Sagie et al.
1987; Patton et al. 1989; Talwar and Smith 1989).
In 1992, Nance and Berry reviewed 140 cases of CS,
in an effort to define diagnostic criteria for the condi-
tion. Requisite criteria included poor growth and neu-
rologic abnormality, with other commonmanifestations
including sensorineural hearing loss, cataracts, pigmen-
tary retinopathy, cutaneous photosensitivity, and dental
caries. The mean age at death was slightly 112 years,
with some affected individuals living into their late
teens. On the other hand, prenatal growth failure, severe
neurologic dysfunction from birth, and development of
cataracts during the first 3 years of life were predictors
of severe disease and early death. This latter category
was designated “type 2” CS, and the original case of
CAMFAK syndrome (reported by the same institution)
was included as a case of type 2 CS. This latter category
of severe, early-onset CS clearly overlapped COFS syn-
drome, in symptoms.
Because of (a) dermatologic similarities between CS
and XP and (b) the discovery that XP results from de-
fects in DNA repair, various assays of UV sensitivity
and DNA repair were performed on CS cells. Patients
with CS were found to have increased sensitivity to kill-
ing from UV radiation, with delayed recovery of RNA
(and DNA) synthesis after UV but with normal UDS.
NER processes remove helix-distorting changes induced
by some carcinogens as well as by UV exposure. XP,
CS, and photosensitive forms of trichothiodystrophy
(TTD [MIM 601675]) are caused by mutations in genes
involved in NER. At least two NER subpathways can
be differentiated: (1) rapid TC-NER, which eliminates
lesions from the transcribed strand of active genes (thus
permitting rapid resumption of transcription), and (2)
GG-NER, which surveys the remainder of the genome
and can be less rapid, depending on the type of lesion.
Both processes are affected in most patients with either
XP or UV-sensitive TTD (except in the case of XP-C,
in which there is a defect in GG-NER only), whereas
only TC-NER is impaired in CS. Since most NER genes
are now cloned, it is possible to identify disease-causing
mutations and to correlate genotypes with phenotypes
(table 3).
Dry scaly skin, abnormal pigmentation on sun-ex-
posed areas, photosensitivity, and predisposition to skin
cancer are cardinal features of XP, and this autosomal
recessive phenotype has been associated with mutations
in one of a number of genes playing a role in NER
(table 3). Mutations in some of these genes, particularly
in the case of XPD, can also cause the related condi-
tions: TTD (which is characterized by brittle, sulfur-
deficient hair with or without short stature, mental re-
tardation, ichthyosis, subtle dysmorphism, and
photosensitivity) and CS (which is characterized by pro-
found growth retardation, pigmentary retinopathy with
optic atrophy, cataracts, mental retardation, wizened
facies, and neurological deterioration). Although there
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Table 3
Overview of Disorders Associated with NER Deficiency
Mutated Gene
Sun-Sensitive
Skin Only XP
XP with
Neurological
Complications CS XPCS TTD
UV-Sensitive
COFS Syndrome
XPA X X
XPB X X
XPC X
XPD Xa X X Xa X X Xb
XPE (x) X
XPF X (x)
XPG X X X X
XPV/RAD30Ac (x) X
CSA X
CSB X X
TTDA X
UVS X
NOTE.—The clinical phenotype associated with a particular gene depends on either the type or the
severity of the mutation involved. “X” denotes presence of the disorder; “(x)” denotes presence in only
some of the patients.
a Source: unpublished observations of two authors (N.G.J.J. and A.R.) of the present article.
b Source: present study.
c Defect not in NER but, rather, in translesion DNA replication; added for completeness.
is some clinical overlap in phenotype, the latter two
syndromes usually do not show either sun-damaged skin
or predisposition to skin cancer. XP and TTD are as-
sociated with different types of mutations in the XPD
gene, and mutation at any one given site is thought to
be predictive of the specific phenotype.
CS is usually caused by mutations in either the CSA
or CSB genes, which result in a selective defect of TC-
NER. However, more rarely, CS may also involve de-
fects in the XPB, XPD, or XPG genes, and in these
cases there is an overall defect in both NER modes,
which often results in symptoms of XP as well, a con-
dition termed “XP-CS complex” (Moriwaki et al.
1996). The patient presented here fits this category and
carries a mutation in the XPD gene, a situation that is
unusual in a number of respects. First, association be-
tween COFS syndrome and XP-D has not been observed
in earlier studies. Second, residual UDS is very low, en-
tirely unlike other defects in the XPD gene that have
been described thus far, in which significant residual
UDS (i.e., 10%–60%) is commonly seen and in which
even virtually normal levels may occur (N.G.J.J., A.R.,
and W.J.K., unpublished data). Third, the causative
D681N mutation in this patient is unique and distinct
from those in two other patients with mutations in the
XPD gene and with XP-CS complex (see fig. 3D). Mu-
tations in the XPD gene can be associated with distinct
inherited conditions (Lehmann 2001), because of the
dual involvement of the XPD protein in NER and basal
transcription. Depending on the mutation, the balance
between these two functions appears to be disturbed in
distinct ways (Vermeulen et al. 2001). All disease-caus-
ing mutations found are subtle (usually they are mis-
sense point mutations), allowing for very substantial
residual rates of basal transcription. Although the con-
founding influence of genetic background can never be
fully dismissed, this importance of the mutation type is
underlined by the finding that the causative mutations
in the XPD gene in XP, TTD, or XP-CS complex show
no overlap (Lehmann 2001). Furthermore, substitution
D681N was also found in one compound heterozygote
patient with XP (Lehmann 2001), together with a typ-
ical XP-associated mutation, suggesting that the latter
allele is a less severely affected one.
Other patients diagnosed with COFS syndrome with
concomitant cellular UV sensitivity have been reported
as having mutations in the XPG gene (Hamel et al.
1996; Sigmundsson et al. 1998) and in the CSB gene
(Meira et al. 2000; Powell et al. 2001). Since these genes
overlap with those known to cause CS symptoms, we
expect that future cases of COFS syndrome will be re-
ported that have mutations in the XPB and CSA genes
as well. We conclude that patients with UV-sensitive
COFS syndrome should be added to the spectrum of
individuals affected by the NER syndromes, which in-
clude XP, CS, and TTD.
Meira et al. (2000, p. 1227) have suggested that
“COFS syndrome … represents an allelic, clinically se-
vere form of CS.” However, some patients with COFS
syndrome have also been found to have normal UV
sensitivity in vitro (N.G.J.J., A.R., and W.J.K., unpub-
lished data). Given both the clinical overlap between
COFS syndrome, Martsolf syndrome, andMICRO syn-
drome and the fact that no previously reported patient
with the latter two syndromes has been studied for UV
sensitivity, we suggest that the term “COFS syndrome”
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be reserved for those patients with demonstrated UV
sensitivity. Martsolf syndrome consists of microcephaly,
mental retardation, cataracts, hypogonadism, and hy-
pertrichosis (Martsolf et al. 1978; Sa´nchez et al. 1985;
Hennekam et al. 1988; Strisciuglio et al. 1988; Harbord
et al. 1989). MICRO syndrome was described in a con-
sanguineous Pakistani family in which two sibs and a
cousin were affected by microcephaly, microcornea, se-
vere mental retardation, hypotonic spastic diplegia, op-
tic atrophy, hypertrichosis, and hypogenitalism (War-
burg et al. 1993). Gyral abnormalities were briefly
mentioned by Warburg et al. (1993), along with hy-
poplasia of the corpus callosum, and Nassogne et al.
(2000) reported a case of MICRO syndrome with pro-
gressive motor neuropathy and polymicrogyria. It is not
known whether the siblings with MICRO syndrome
who were reported by Warburg et al. had polymicro-
gyria or progressive motor neuropathy, but some pre-
vious cases of COFS syndrome were reported with cor-
tical abnormalities before the pathogenesis of this
condition became known (Lurie et al. 1976; Sakai et al.
1997). Those patients with a similar phenotype but with
normal UV sensitivity should be temporarily considered
as having MICRO syndrome or Martsolf syndrome (al-
though further clinical and biochemical differentiation
between these two syndromes is needed). These findings
indicate that DNA-repair studies will not be useful for
identifying all patients within this spectrum of auto-
somal recessive eye-brain disorders and that more study
will be needed to determine whether all patients with
COFS syndrome have a DNA-repair abnormality that
could be regarded as a subtype of CS.
We conclude that UV-sensitivity tests in cases with
suspected COFS syndrome are important as a means to
refine the initial diagnosis. The finding of cellular UV
sensitivity, although not evident in all patients who pre-
sent with features suggestive of COFS syndrome, pro-
vides a biochemical marker, which allows for optimal
genetic counseling and management of future pregnan-
cies. Here we have presented the first example of pre-
natal diagnosis of COFS syndrome, on the basis of NER
studies in two consecutive pregnancies in the same fam-
ily, in which one of the prenatal diagnoses was com-
plicated by the presence of multiple fetuses. We have
shown here, with the caveat regarding the possibility of
cross-contamination in CV sampling in multiple preg-
nancies, that biochemical repair parameters allow re-
liable prenatal testing of patients with UV-sensitive
COFS syndrome, without the need for time-consuming
and costly gene assignment and sequencing procedures
as a prerequisite.
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